Pulmatrix says to present 'promising' new data at CF conference
Pulmatrix announced it will present "promising new preclinical data" about its inhaled antifungal drug PUR1900 in a poster at the North American Cystic Fibrosis Conference. The poster will be presented during the conference in Orlando, Florida, October 27-29. "The preclinical study comparing PUR1900 to the oral reference product shows that PUR1900 offers a significant advantage over the current standard of care for treating fungal infections in the lungs. The profile of PUR1900 demonstrated in this study, with high lung exposure and low systemic levels, should be well suited for treating fungal infections. Our goal is to translate this profile in our upcoming clinical trials which will help us establish optimal dosing parameters for patients," said David Hava, Ph.D., Chief Scientific Officer for Pulmatrix.